These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 9131500

  • 21. Gonadotropin-releasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones.
    Malik M, Britten J, Cox J, Patel A, Catherino WH.
    Fertil Steril; 2016 Jan; 105(1):214-24. PubMed ID: 26409322
    [Abstract] [Full Text] [Related]

  • 22. Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists.
    Cheng YM, Chou CY, Huang SC, Lin HC.
    BJOG; 2001 Jan; 108(1):95-102. PubMed ID: 11213012
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. GnRH agonist for intravenous leiomyomatosis with cardiac extension. A case report.
    Mitsuhashi A, Nagai Y, Sugita M, Nakajima N, Sekiya S.
    J Reprod Med; 1999 Oct; 44(10):883-6. PubMed ID: 10554751
    [Abstract] [Full Text] [Related]

  • 25. [GnRH agonists and antagonists in the preoperative therapy of uterine fibroids: literature review].
    De Falco M, Pollio F, Pontillo M, Ambrosino E, Busiello A, Carbone IF, Ciociola F, Di Nardo MA, Landi L, Di Lieto A.
    Minerva Ginecol; 2006 Dec; 58(6):553-60. PubMed ID: 17108883
    [Abstract] [Full Text] [Related]

  • 26. Gonadotropin releasing hormone (GnRH) agonist therapy for reduction of leiomyoma volume.
    Murphy NJ, Wallace DL.
    Gynecol Oncol; 1993 May; 49(2):266-7. PubMed ID: 8504999
    [Abstract] [Full Text] [Related]

  • 27. GnRH-antagonists in reproductive medicine.
    Griesinger G, Felberbaum R, Diedrich K.
    Arch Gynecol Obstet; 2005 Dec; 273(2):71-8. PubMed ID: 15991015
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Preoperative treatment of uterine leiomyomas: clinical findings and expression of transforming growth factor-beta3 and connective tissue growth factor.
    De Falco M, Staibano S, D'Armiento FP, Mascolo M, Salvatore G, Busiello A, Carbone IF, Pollio F, Di Lieto A.
    J Soc Gynecol Investig; 2006 May; 13(4):297-303. PubMed ID: 16697947
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [GnRH analogues in the management of uterine leiomyoma].
    Matsuo H, Maruo T.
    Nihon Rinsho; 2006 Apr; 64 Suppl 4():75-9. PubMed ID: 16689288
    [No Abstract] [Full Text] [Related]

  • 32. Ovarian estradiol production in vivo. Inhibitory effect of leuprolide acetate.
    Kowalik A, Barmat L, Damario M, Liu HC, Davis O, Rosenwaks Z.
    J Reprod Med; 1998 May; 43(5):413-7. PubMed ID: 9610463
    [Abstract] [Full Text] [Related]

  • 33. Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
    Massoud W, Paparel P, Lopez JG, Perrin P, Daumont M, Ruffion A.
    Int J Urol; 2006 Mar; 13(3):303-4. PubMed ID: 16643633
    [Abstract] [Full Text] [Related]

  • 34. Inhibition of in situ expression of aromatase P450 in leiomyoma of the uterus by leuprorelin acetate.
    Shozu M, Sumitani H, Segawa T, Yang HJ, Murakami K, Inoue M.
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5405-11. PubMed ID: 11701714
    [Abstract] [Full Text] [Related]

  • 35. Association of the shrinkage of uterine leiomyoma treated with GnRH agonist and deletion of long arm of chromosome 7.
    Takahashi K, Kawamura N, Tsujimura A, Ichimura T, Ito F, Ishiko O, Ogita S.
    Int J Oncol; 2001 Jun; 18(6):1259-63. PubMed ID: 11351260
    [Abstract] [Full Text] [Related]

  • 36. Aromatase and leiomyoma of the uterus.
    Shozu M, Murakami K, Inoue M.
    Semin Reprod Med; 2004 Feb; 22(1):51-60. PubMed ID: 15083381
    [Abstract] [Full Text] [Related]

  • 37. Immunohistochemical detection of insulin-like growth factor type I receptor and uterine volume changes in gonadotropin-releasing hormone analog-treated uterine leiomyomas.
    Di Lieto A, Iannotti F, De Falco M, Staibano S, Pollio F, Ciociola F, De Rosa G.
    Am J Obstet Gynecol; 2003 Mar; 188(3):702-6. PubMed ID: 12634644
    [Abstract] [Full Text] [Related]

  • 38. Semiquantitative assessment of MR imaging in prediction of efficacy of gonadotropin-releasing hormone agonist for volume reduction of uterine leiomyoma: initial experience.
    Okuda S, Oshio K, Shinmoto H, Tanimoto A, Asada H, Fujii T, Yoshimura Y, Kuribayashi S.
    Radiology; 2008 Sep; 248(3):917-24. PubMed ID: 18710984
    [Abstract] [Full Text] [Related]

  • 39. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas.
    Di Lieto A, De Falco M, Pollio F, Mansueto G, Salvatore G, Somma P, Ciociola F, De Rosa G, Staibano S.
    J Soc Gynecol Investig; 2005 Feb; 12(2):123-8. PubMed ID: 15695108
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.